JP6431528B2 - 癌治療のための薬物局所送達装置及び方法 - Google Patents

癌治療のための薬物局所送達装置及び方法 Download PDF

Info

Publication number
JP6431528B2
JP6431528B2 JP2016507662A JP2016507662A JP6431528B2 JP 6431528 B2 JP6431528 B2 JP 6431528B2 JP 2016507662 A JP2016507662 A JP 2016507662A JP 2016507662 A JP2016507662 A JP 2016507662A JP 6431528 B2 JP6431528 B2 JP 6431528B2
Authority
JP
Japan
Prior art keywords
drug
paclitaxel
chemotherapeutic agent
film
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016507662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516780A5 (enExample
JP2016516780A (ja
Inventor
インドルフィ，ローラ
アール． エデルマン，イレイザー
アール． エデルマン，イレイザー
エス． ランガー，ロバート
エス． ランガー，ロバート
ダブリュ． クラーク，ジェフリー
ダブリュ． クラーク，ジェフリー
ティー． ティン，デイビッド
ティー． ティン，デイビッド
ローザ アンナマリア フェロン，クリスティーナ
ローザ アンナマリア フェロン，クリスティーナ
リゴーリオ，マッテオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2016516780A publication Critical patent/JP2016516780A/ja
Publication of JP2016516780A5 publication Critical patent/JP2016516780A5/ja
Application granted granted Critical
Publication of JP6431528B2 publication Critical patent/JP6431528B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2002/041—Bile ducts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0017—Angular shapes
    • A61F2230/0021—Angular shapes square
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00—Materials or methods for coatings medical devices
    • A61L2420/06—Coatings containing a mixture of two or more compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Polymers & Plastics (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016507662A 2013-04-10 2014-04-10 癌治療のための薬物局所送達装置及び方法 Active JP6431528B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361810543P 2013-04-10 2013-04-10
US61/810,543 2013-04-10
PCT/US2014/033671 WO2014169137A1 (en) 2013-04-10 2014-04-10 Local drug delivery devices and methods for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018207608A Division JP2019034962A (ja) 2013-04-10 2018-11-02 癌治療のための薬物局所送達装置及び方法

Publications (3)

Publication Number Publication Date
JP2016516780A JP2016516780A (ja) 2016-06-09
JP2016516780A5 JP2016516780A5 (enExample) 2017-06-08
JP6431528B2 true JP6431528B2 (ja) 2018-11-28

Family

ID=50841949

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016507662A Active JP6431528B2 (ja) 2013-04-10 2014-04-10 癌治療のための薬物局所送達装置及び方法
JP2018207608A Pending JP2019034962A (ja) 2013-04-10 2018-11-02 癌治療のための薬物局所送達装置及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018207608A Pending JP2019034962A (ja) 2013-04-10 2018-11-02 癌治療のための薬物局所送達装置及び方法

Country Status (6)

Country Link
US (4) US9301926B2 (enExample)
EP (1) EP2983730B1 (enExample)
JP (2) JP6431528B2 (enExample)
CA (1) CA2944480C (enExample)
ES (1) ES2762555T3 (enExample)
WO (1) WO2014169137A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019034962A (ja) * 2013-04-10 2019-03-07 マサチューセッツ インスチテュート オブ テクノロジーＭａｓｓａｃｈｕｓｅｔｔｓ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｔｅｃｈｎｏｌｏｇｙ 癌治療のための薬物局所送達装置及び方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104812395A (zh) 2012-08-31 2015-07-29 塔里斯生物医药公司 用于治疗前列腺的药物递送系统和方法
EP3797768A1 (en) 2014-06-23 2021-03-31 Placon Therapeutics, Inc. Maleimide-functionalised platinum for use in the treatment of cancer
US10751319B2 (en) 2015-06-04 2020-08-25 Crititech, Inc. Collection device and methods for use
LT3865484T (lt) 2015-07-07 2024-02-12 H. Lundbeck A/S Pde9 inhibitorius su imidazopirazinono karkasu, skirtas periferinių ligų gydymui
EP3439635B1 (en) 2016-04-04 2020-12-09 Crititech, Inc. Formulations for solid tumor treatment
IL295973A (en) 2016-07-06 2022-10-01 H Lundbeck As pde9 inhibitors for the treatment of peripheral diseases
DK3624887T3 (da) * 2017-05-17 2025-05-19 Massachusetts Inst Technology Vævforankringsartikler
US11370795B2 (en) 2017-05-26 2022-06-28 Imara Inc. Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
SG10201913649TA (en) 2017-06-09 2020-03-30 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
KR102303762B1 (ko) 2017-06-14 2021-09-23 크리티테크, 인크. 폐 장애의 치료 방법
BR112020000832A2 (pt) 2017-07-25 2020-07-21 Taris Biomedical Llc métodos para tratar metástase tumoral
BR112020005814A2 (pt) 2017-10-03 2020-09-24 Crititech, Inc. administração local de partículas antineoplásicas em combinação com administração sistêmica de agentes imunoterapêuticos para o tratamento de câncer
IL274343B2 (en) 2017-11-08 2023-10-01 Taris Biomedical Llc Treatment methods and maintenance treatment for bladder cancer using gemcitabine
EP3717035B1 (en) * 2017-11-30 2023-10-25 Anatoli D. Dosta Porous polytetrafluoroethylene for use in a method of inhibiting tumor cell growth
EP3793667A1 (en) 2018-05-17 2021-03-24 Massachusetts Institute of Technology Systems for electrical stimulation
SG11202005949UA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
AU2019275406B2 (en) 2018-05-24 2024-11-14 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
HRP20240363T1 (hr) 2018-05-25 2024-06-07 Cardurion Pharmaceuticals, Inc. Monohidratni i kristalni oblici 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a] pirazin-8-ona
WO2020047311A1 (en) 2018-08-31 2020-03-05 Imara Inc. Pde9 inhibitors for treating sickle cell disease
US12472148B2 (en) 2021-04-26 2025-11-18 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
IL312842A (en) * 2021-11-17 2024-07-01 Panther Therapeutics Inc Implantable and biodegradable drug delivery devices and methods of using them
AU2023314589A1 (en) * 2022-07-22 2025-02-06 PanTher Therapeutics, Inc. Tissue penetrating and biodegradable drug delivery devices and methods of use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US20050271701A1 (en) 2000-03-15 2005-12-08 Orbus Medical Technologies, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9216239B2 (en) 2001-06-08 2015-12-22 Leo Rubin Medical device for intra-lumenal delivery of pharmaceutical agents
JP2005160600A (ja) * 2003-12-01 2005-06-23 Ir:Kk 液含浸性ステント及び薬液含浸ステント
JP5028605B2 (ja) * 2004-11-22 2012-09-19 国立大学法人九州大学 バイオフィルム形成阻害剤及び治療用器具
US20110118827A1 (en) 2005-06-06 2011-05-19 Dr. Tim Wu Biodegradable stent formed with polymer-bioceramic nanoparticle composite and method of making the same
US20070178138A1 (en) 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
EP2019649A4 (en) * 2006-04-27 2012-09-19 Narmada R Shenoy COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING BODILUM DISORDER DISORDERS
JP2007313009A (ja) * 2006-05-25 2007-12-06 Terumo Corp ステント
US9474833B2 (en) * 2006-12-18 2016-10-25 Cook Medical Technologies Llc Stent graft with releasable therapeutic agent and soluble coating
AU2008202283B2 (en) 2007-06-01 2011-01-20 Kyong-Min Shin Coating agent for drug releasing stent, preparation method thereof and drug releasing stent coated therewith
KR100904207B1 (ko) 2007-06-01 2009-06-25 (주) 태웅메디칼 스텐트용 약물 방출 코팅제, 그의 제조방법 및 이 코팅제로 코팅된 약물 방출 스텐트
KR100988816B1 (ko) 2008-01-29 2010-10-20 신경민 담즙관용 이중 피막형 스텐트
AU2009324464B2 (en) * 2008-12-11 2016-05-05 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20110045055A1 (en) * 2009-08-21 2011-02-24 Boston Scientific Scimed, Inc. Medical devices containing therapeutic agents
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US20120150282A1 (en) 2010-12-10 2012-06-14 Biotronik Ag Implant having a paclitaxel-releasing coating
EP2696815B1 (en) 2011-04-13 2019-03-20 Micell Technologies, Inc. Stents having controlled elution
US9006199B2 (en) 2011-11-14 2015-04-14 Silenseed Ltd. Methods and compositions for treating prostate cancer
CN102727944A (zh) * 2011-11-14 2012-10-17 上海市第一人民医院 抗胆管良、恶性狭窄的药物涂层支架及制备方法
US8834902B2 (en) * 2012-03-09 2014-09-16 Q3 Medical Devices Limited Biodegradable supporting device
EP2983730B1 (en) * 2013-04-10 2019-10-16 Massachusetts Institute of Technology Local drug delivery devices and methods for treating cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019034962A (ja) * 2013-04-10 2019-03-07 マサチューセッツ インスチテュート オブ テクノロジーＭａｓｓａｃｈｕｓｅｔｔｓ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｔｅｃｈｎｏｌｏｇｙ 癌治療のための薬物局所送達装置及び方法

Also Published As

Publication number Publication date
US20140308336A1 (en) 2014-10-16
WO2014169137A1 (en) 2014-10-16
US11167066B2 (en) 2021-11-09
US9301926B2 (en) 2016-04-05
EP2983730B1 (en) 2019-10-16
US20220054719A1 (en) 2022-02-24
ES2762555T3 (es) 2020-05-25
US20240238485A1 (en) 2024-07-18
CA2944480A1 (en) 2014-10-16
EP2983730A1 (en) 2016-02-17
JP2019034962A (ja) 2019-03-07
CA2944480C (en) 2021-05-18
US20160175491A1 (en) 2016-06-23
JP2016516780A (ja) 2016-06-09

Similar Documents

Publication Publication Date Title
JP6431528B2 (ja) 癌治療のための薬物局所送達装置及び方法
Yi et al. A 3D-printed local drug delivery patch for pancreatic cancer growth suppression
RU2242974C2 (ru) Композиции и способы лечения или предупреждения воспалительных заболеваний
JP2021107420A (ja) 埋込み型薬物送達組成物およびその使用法
Moon et al. An acetylated polysaccharide-PTFE membrane-covered stent for the delivery of gemcitabine for treatment of gastrointestinal cancer and related stenosis
JP2013212418A (ja) 一時的補剛メッシュ補綴具
CN103140226A (zh) 用于治疗脊髓损伤的制剂
JP2016516780A5 (enExample)
WO2007058190A1 (ja) 薬剤放出制御組成物および薬剤放出性医療器具
TW200800196A (en) Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
KR20200032159A (ko) 종양 전이를 치료하는 방법
AU2008202283A1 (en) Coating agent for drug releasing stent, preparation method thereof and drug releasing stent coated therewith
US20060193893A1 (en) Medical devices
CN100464789C (zh) 抗癌药物粒子消化道支架
Yu et al. Development of a rapidly made, easily personalized drug-eluting polymer film on the electrode array of a cochlear implant during surgery
KR100916750B1 (ko) 약물 방출 스텐트용 코팅제와 약물 방출 스텐트용 코팅제의제조방법
Zhao et al. Rational design of drug-eluting stents via electrospray and in vivo evaluation of preventing oesophageal stricture
CN102363052A (zh) 携带短链神经酰胺的药物支架
WO2010072109A1 (zh) 一种肿瘤治疗药物的缓释体系
ES2948916T3 (es) Nanopartículas de óxido nítrico sintasa para el tratamiento de la enfermedad vascular
JP2024540512A (ja) 埋め込み型生分解性薬物送達デバイス及びその使用方法
Park et al. In vitro/in vivo evaluation of NCDS-micro-fabricated biodegradable implant
JP2025524885A (ja) 組織貫通型及び生分解性の薬物送達デバイス及びその使用方法
CN120983712A (zh) 一种单侧控释免疫药物的多层覆膜支架及其制备方法和应用
EP4056207A1 (en) Drug-loaded implanted medical device and preparation method therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180126

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181102

R150 Certificate of patent or registration of utility model

Ref document number: 6431528

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250